Study reveals effects of weight-loss drugs on adolescents

Obese adolescents who have been prescribed popular weight-loss medications like Ozempic, Wegovy, and Mounjaro may be less likely to have suicidal thoughts and self-harm behaviors. A new study has found that adolescents using glucagon-like peptide 1 receptor (GLP1R) agonists are less likely to attempt self-harm.

The study was conducted by researchers in Israel and published in JAMA Pediatrics. He specifically looked at weight loss drugs, which include brands like Ozempic, Wegovy and Mounjaro. These medications were originally created to effectively treat diabetes. However, they have gained popularity due to their ability to help people lose weight by reducing appetite and slowing digestion.

The research observed the medical records of nearly 7,000 adolescents aged 12 to 18 diagnosed with obesity. They were then divided into two groups: the first group consisted of adolescents who were prescribed GLP1R medications, and the second group consisted of adolescents receiving lifestyle interventions, such as health counseling. of diet and exercise, without medication.

What did the study reveal?
The results were striking. Those who took the GLP1R medications had a 33 percent lower risk of suicidal ideation over the course of a year compared to those who did not take the medications and did not initiate behavioral interventions. According to the researchers, the results persisted for three years.

Although the reasons for this finding are unclear, scientists have pointed to a theory that successful weight loss leads to improved mental health and self-esteem in adolescents. Another theory is that the drugs could have direct effects on the brain, potentially influencing mood and behavior.

Side effects of weight loss drugs
During the study, researchers discovered some expected side effects of the drugs. Adolescents taking GLP1R medications were more likely to experience gastrointestinal symptoms such as nausea and vomiting. However, they had a lower risk of acute pancreatitis, a potentially serious illness associated with these drugs.